

Diagnostics for type 1 diabetes mellitus.





Type 1 diabetes mellitus: a chronic autoimmune disease

Course and forms

Type 1 diabetes mellitus (insulin-dependent diabetes mellitus, T1DM) is a chronic autoimmune disease in which the beta cells of the pancreatic islets of Langerhans (see fig. 1) are selectively destroyed through the mediation of T lymphocytes and specific autoantibodies (AAb) against beta cells. As a result, the pancreas is unable to produce insulin and the blood glucose level can no longer be regulated.

The exact cause is still unclear, but genetic predisposition and infections are considered risk factors. Although the disease often starts in childhood or at the beginning of puberty, it can also occur in adults. The global annual incidence of T1DM is estimated to be about 130,000 new cases in persons under the age of 20,¹ and the incidence in children is currently estimated to be increasing by 3 to 4% per year in countries with a high standard of living.²

Testing for disease-relevant autoantibodies:

- To support the diagnosis of type 1 diabetes mellitus including LADA
- Important tool for the differentiation from other forms of diabetes, e. g. type 2
- Autoantibodies described as predictive and early markers




Figure 1: Islet cells of Langerhans with beta cells in the pancreas

Patients generally require lifelong treatment with exogenous insulin. The earlier T1DM is diagnosed and treated, the better the prognosis.

A special form of T1DM is LADA (latent autoimmune diabetes in adults). It manifests around the age of 25 and is characterised by a mild course during which insulin dependence slowly develops. LADA is often initially misdiagnosed as type 2 diabetes mellitus, a non-auto-immune form of diabetes. Therefore, the detection of disease-specific autoantibodies is important to aid in the diagnosis of T1DM and to differentiate the disease from other forms of diabetes.²⁻⁶




Figure 2: Stages of T1DM (adapted after Insel et al.⁷ and the American Diabetes Association Professional Practice Committee⁵)



The number of antibody specificities present correlates with the likelihood of developing T1DM (see fig.3)⁸. As autoantibodies are important predictive early markers,^{3,5,9} guidelines describe the antibody screening as useful, for example, in individuals at increased risk of developing the disease to identify presymptomatic T1DM.⁵




Figure3: Increasing likelihood of developing T1DM with increasing number of different specific autoantibodies (adapted after Ziegler et al.⁸)

Autoantibodies associated with type 1 diabetes mellitus

The results of many international studies have shown that several specific autoantibodies directed against various pancreatic islet cell antigens (ICA) are associated with T1DM (see on the right page). These often occur several months to years before the disease manifests, which has led to the classification of T1DM into stages (see fig.2 on the previous page).^{7,5} The prevalence of each ICA varies greatly with age (often peaking in childhood and declining with increasing age). At least one ICA can be detected in 85–90 % of patients with new-onset T1DM at the time of diagnosis.³

Anti-glutamic acid decarboxylase antibodies (GADA)

- Directed against glutamic acid decarboxylase (GAD), which catalyses the conversion of glutamic acid to gamma-aminobutyric acid, an inhibitory neurotransmitter that stimulates the production of proinsulin
- Occurrence: often in very high concentrations with long persistence
- Prevalence: 65–80 % in newly diagnosed patients³
- The most sensitive marker in LADA patients¹⁰
- GADA also occur, for example, in stiff-person syndrome, a neurological autoimmune disease associated with muscle stiffness and spasms.¹¹

Anti-tyrosine phosphatase antibodies (IA2A)

- Directed against insulinoma-associated antigen 2 (IA2), an enzymatically inactive tyrosine phosphatase that is expressed in beta cells and neuroendocrine tissues and involved in the regulation of insulin secretion
- Occurrence: often together with other disease-specific autoantibodies
- Prevalence: 65–80 % in newly diagnosed patients³
- High diagnostic sensitivity in children and adolescents regarding rapid progression to manifest type 1 diabetes mellitus¹²

Anti-zinc transporter 8 antibodies (ZnT8A)

- Directed against zinc transporter 8 (ZnT8), a transmembrane cation transporter that is expressed on the cell membrane of secretory granules in beta cells
- Occurrence: in 26 % of patients with type 1 diabetes mellitus with no detectable autoantibodies against GAD, IA2 or insulin¹³
- Prevalence: 60–80 % in patients at the beginning of the disease¹³

Anti-islet cell antibodies (ICA)

- All antibodies directed against endocrine cells of the pancreas
- Detectable using indirect immunofluorescence test (IIFT)
- Prevalence in manifest T1DM: 80–90 %¹⁴
- Most ICA bind to the antigens GAD, IA2 and/or ZnT8.

Anti-insulin autoantibodies (IAA)

- Occurrence: in the majority of paediatric patients, less frequent with increasing age
- Determination under insulin therapy is not recommended, as IAA induced by exogenous insulin cannot be distinguished from IAA against the body's own insulin.

The prevalence data on this page should be treated with caution due to the heterogeneity of the data between studies.

Possible diagnostic application of diabetes-associated antibodies




Figure 4: Example scheme (adapted after Holt et al.⁹, Thaler et al.¹⁵ and international guidelines)
The determination of autoantibodies can be performed in sequences, with confirmation of suspected T1DM with the first positive test. The combined determination of all antibodies is useful up to the age of 20 due to the age-dependent antibody prevalences. From the age of 20, it may be advisable to test for GADA first and then for IA2A or ZnT8A. The combined determination of autoantibodies against all four antigens provides the most reliable detection of T1DM at the onset of the disease (up to over 96 % of cases¹⁶). Direct quantitative determination of autoantibodies is preferable.^{9, 15}

Order information

Test system	Test name	Antibodies against	Antigen/ substrate	Order no.
ELISA	Anti-GAD ELISA	65kDa isoform of glutamic acid decarboxylase (GAD)	Antigen-coated microplate wells	EA 1022-9601-2
	Anti-IA2 ELISA	Tyrosine phosphatase (IA2)		EA 1023-9601-2
	Anti-Zinc Transporter 8 ELISA	Zinc transporter 8 (ZnT8)		EA 1027-9601
IIFT	IIFT Pancreas (Monkey)	Pancreatic islet cells (IC)	Primate pancreas	FA 1020-####

As up to 30 % of T1DM patients also develop other autoimmune diseases such as autoimmune thyroiditis, autoimmune gastritis and coeliac disease, further diagnostics are recommended.¹⁷

References

1. Patterson CC et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 157:107842 (2019).
2. World Health Organization (WHO), Genf. Classification of Diabetes Mellitus. (2019).
3. AWMF und Deutsche Diabetes Gesellschaft (DDG). S3-Leitlinie Therapie des Typ-1-Diabetes, 2. Auflage (2018), AWMF-Registernummer: 057-013. <https://register.awmf.org/de/leitlinien/detail/057-013> (aufgerufen am 20.06.2023).
4. AWMF und Deutsche Diabetes Gesellschaft (DDG). S3-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter 4. Auflage (2023), AWMF-Registernummer: 057-016. <https://register.awmf.org/de/leitlinien/detail/057-016> (aufgerufen am 03.02.2025).
5. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. *Diabetes Care* 48(Suppl 1):27–49 (2025).
6. Ziegler AG, Nepom GT. Prediction and Pathogenesis in Type I Diabetes. *Immunity* 32(4):468–478 (2010).
7. Insel RA et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care* 38(10):1964–1974 (2015).
8. Ziegler AG et al. Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children. *JAMA* 309(23):2473–2479 (2013).
9. Holt RIG et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 64:2609–2652 (2021).
10. Buzzetti R et al. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. *Diabetes* 69(10):2037–2047 (2020).
11. AWMF und Deutsche Gesellschaft für Neurologie (DGN). S1-Leitlinie Stiff-Man-Syndrom (Stiff-Person-Syndrom) (2017), AWMF-Registernummer 030/080. <https://register.awmf.org/de/leitlinien/detail/030-080> (aufgerufen am 12.07.2023).
12. Felton JL et al. Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review. *Commun Med (Lond)* 4(1):66 (2024).
13. Wenzlau JM et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. *Proc Natl Acad Sci USA* 104(43):17040–17045 (2007).
14. Seissler J, Scherbaum WA. Stellenwert der Autoimmundiagnostik bei Diabetes mellitus. *J Lab Med* 29(4):246–250 (2005).
15. Thaler M et al. Auto-Antikörper-Diagnostik in der Diabetologie – Aktueller Stand der Analytik und klinische Anwendung in Deutschland. *Diabetologie* 17:382–388 (2022).
16. Wenzlau, JM, Hutton JC. Novel Diabetes Autoantibodies and Prediction of Type 1 Diabetes. *Curr Diab Rep* 13(5):608–615 (2013).
17. Lechleitner M et al. Autoimmunerkrankungen bei Typ 1 Diabetes. *Wien Klin Wochenschr* 128 (Suppl 2), 201–203 (2016).

Find out more at
www.euroimmun.com
 or contact us directly:
www.euroimmun.com/contact

